{
    "nct_id": "NCT05176223",
    "official_title": "Optimizing Outcomes of Patients with Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging",
    "inclusion_criteria": "* Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies\n* Have radiographically measurable disease by RECIST\n* Eligible for atezolizumab/bevacizumab front line therapy\n* Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan\n* Patients with higher than the weight/size limitations of PET/CT scanner",
    "miscellaneous_criteria": ""
}